ArticleUrologic oncology2018
Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database.
Article in Urologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- The impact of diagnosis and treatment of penile cancer on intimacy: a qualitative assessment.International journal of impotence research · 2025Article
- Penile cancer awareness and knowledge among adult patients in an ambulatory urology clinic.Translational andrology and urology · 2025Article
- Exploring the Multifactorial Landscape of Penile Cancer: A Comprehensive Analysis of Risk Factors.Diagnostics (Basel, Switzerland) · 2024Review
- Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study.Translational andrology and urology · 2024Article
- Review
- Article
- The Burden of HPV-Related Hospitalizations: Analysis of Hospital Discharge Records from the Years 2015-2021 from a Southern Italian Region.Pathogens (Basel, Switzerland) · 2023Article
- Clinical Profile and Predictors of Survival in Carcinoma Penis Patients.Current oncology (Toronto, Ont.) · 2023Article
- Increased HRD score in cisplatin resistant penile cancer cells.BMC cancer · 2022Article
- A comprehensive analysis of penile cancer in the region with the highest worldwide incidence reveals new insights into the disease.BMC cancer · 2022Article
- A global approach to improving penile cancer care.Nature reviews. Urology · 2022Review
- Trends in Incidence, Mortality, and Survival of Penile Cancer in the United States: A Population-Based Study.Frontiers in oncology · 2022Article
- Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis.Frontiers in oncology · 2022Article
- Demographic disparities of penile cancer in Appalachian Kentucky.The Canadian journal of urology · 2021Article
- Underutilization of Surgical Standard of Care for Insured Men with Invasive Penile Cancer.Urology practice · 2021Article
- A Clinical Nomogram for Predicting Lymph Node Metastasis in Penile Cancer: A SEER-Based Study.Frontiers in oncology · 2021Article
- Article
- The Diagnosis and Treatment of Penile Cancer.Deutsches Arzteblatt international · 2018Article
- Living in a rural area as a risk factor for worst outcomes in penile cancer.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- Novel Prognostic Models for Patients With Penile Carcinoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesTo evaluate whether socioeconomic factors affect pathologic stage, treatment delays, pathologic upstaging, and overall survival (OS) in patients with penile cancer (PC). PATIENTS AND
methodsA total of 13,283 eligible patients diagnosed with PC from 1998 to 2012 were identified from the National Cancer Database. Socioeconomic, demographic and pathologic variables were used in multivariable regression models to identify predictors of pathologic T stage ≥2, pathologic lymph node positivity, cT to pT upstaging, treatment delays, and OS.
resultsA 5-year OS was 61.5% with a median follow-up of 41.7 months. Pathologic T stage ≥2 was identified in 3,521 patients (27.2%), 1,173 (9.2%) had ≥pN1 and 388 (7.9%) experienced cT to pT upstaging. Variables associated with a higher likelihood of pathologic T stage ≥2 included no insurance (OR = 1.79, P<0.001), lower higher education based on zip code (OR = 1.13, P = 0.027), black race (OR = 1.17, P = 0.046) and Hispanic ethnicity (OR = 1.66, P<0.001). Patients with Hispanic ethnicity (OR = 1.46; P<0.001) or living in nonmetropolitan areas were more likely to have ≥pN1 (P = 0.001). Lack of insurance was associated with cT to pT upstaging (OR = 2.05, P = 0.001) as was living in an urban vs. metropolitan area (OR = 1.35, P = 0.031). In addition to TNM stage, black vs. white race (HR = 1.56, P<0.001), living in an urban vs. metropolitan area (hazard ratio [HR] = 1.18, P = 0.022), age (HR = 1.04, P<0.001) and Charlson score (HR = 1.49, P<0.001) were associated with lower OS.
conclusionSocioeconomic variables including no insurance, lower education, race, Hispanic ethnicity, and nonmetropolitan residence were found to be poor prognostic factors. Increased educational awareness of this rare disease may help reduce delays in diagnosis, improve prognosis and ultimately prevent deaths among socioeconomically disadvantaged men with PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.